Sedative may prevent delirium in critical patients in intensive care
A low dose of the sedative dexmedetomidine given at night may prevent delirium in critically ill patients, researchers say in what they call a practice-altering study
A low dose of the sedative dexmedetomidine given at night may prevent delirium in critically ill patients, researchers say.
Results of a randomised placebo-controlled trial, thought to be the first of its kind to identify a drug to prevent adults developing delirium in intensive care (IC), were published online in the American Journal of Respiratory and Critical Care Medicine.
The study covered 100 patients in intensive care at two hospitals – one in Quebec and the other in Boston – none of whom had delirium at the time of enrolment.
Half the patients were randomly assigned to receive intravenous dexmedetomidine and the other half were infused with the placebo.
Recommended for high-risk patients
The study found that compared with the placebo group, those receiving dexmedetomidine were more likely to remain free of delirium throughout their ICU stay: 80% as opposed to 54%.
Study author Yoanna Skrobik said: ‘In other studies, dexmedetomidine has been associated with lower delirium prevalence rates than other sedatives.
‘But whether dexmedetomidine might actually prevent delirium was not clear.
‘We believe this is a practice-altering study and that dexmedetomidine should be used with patients at high risk for delirium.’
Skrobik Y et al (2018) Low-dose nocturnal dexmedetomidine prevents ICU delirium: a randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine. doi:10.1164/rccm.201710-1995OC